Literature DB >> 2483750

Localization of terminal complement components S-protein and SP-40,40 in renal biopsies.

B F Murphy1, D J Davies, W Morrow, A J d'Apice.   

Abstract

The terminal complement complex has been implicated in the development of glomerular injury in both experimental and, indirectly, in human glomerulonephritis. Recent data suggests that the terminal complement complex in human glomerulonephritis may be in the cytolytically inactive SC5b-9 form which also contains S-protein and a recently identified protein, SP-40,40. In this study renal biopsies were examined by immunofluorescence to determine the incidence and inter-relation of deposition of the SC5b-9 components C6, C9, S-protein and SP-40,40. All components of SC5b-9 were found in arteries and arterioles, along the tubular basement membrane and in areas of glomerulosclerosis in all biopsies. This deposition was sometimes associated with C3 but never immunoglobulin deposition and correlated with the degree of renal injury. In addition, in biopsies with glomerular deposition of immunoglobulin and C3, the SC5b-9, components co-localized with the immune deposits. Glomeruli without immune deposits or glomerulosclerosis contained none of the SC5b-9 components. The incidence and pattern of distribution of SP-40,40 was similar to that of S-protein, C6 and C9 in all of cases. These data confirm that the terminal complement complex in the kidney is, at least partly, in the SC5b-9 form both in the specific immune glomerular deposition and in the "non-specific" deposition in areas of renal injury. SP-40,40 is also found in the SC5b-9 complex in all forms of renal disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2483750     DOI: 10.3109/00313028909061073

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  20 in total

1.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

Review 2.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

3.  V-src-induced-transcription of the avian clusterin gene.

Authors:  Y Herault; G Chatelain; G Brun; D Michel
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

4.  What is clusterin?

Authors:  I B Fritz
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

5.  Interaction of clusterin and matrix metalloproteinase-9 and its implication for epithelial homeostasis and inflammation.

Authors:  Shinwu Jeong; Dolena R Ledee; Gabriel M Gordon; Tatsuo Itakura; Nitin Patel; Aaron Martin; M Elizabeth Fini
Journal:  Am J Pathol       Date:  2012-03-20       Impact factor: 4.307

6.  Potential role of apolipoprotein-E in fibrillogenesis.

Authors:  G Gallo; T Wisniewski; N H Choi-Miura; J Ghiso; B Frangione
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

7.  Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers.

Authors:  H Dauchel; P Joly; A Delpech; E Thomine; F Sauger; X Le Loet; P Lauret; F Tron; M Fontaine; J Ripoche
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

8.  Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease).

Authors:  J H Jansen; K Høgåsen; T E Mollnes
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

9.  Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions.

Authors:  D P Witte; B J Aronow; M L Stauderman; W D Stuart; M A Clay; R A Gruppo; S H Jenkins; J A Harmony
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

10.  Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits.

Authors:  G Gallo; F Goñi; F Boctor; R Vidal; A Kumar; F J Stevens; B Frangione; J Ghiso
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.